Description
Olanib 150 MG (Olaparib) is a first-in-class, orally bioavailable, potent inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes specifically PARP1, PARP2, and PARP3 a small-molecule nicotinamide pharmacophore-based inhibitor that occupies the NAD+-binding pocket of PARP enzymes, competitively blocking the PARP catalytic site and preventing PARP-mediated synthesis of poly(ADP-ribose) (PAR) chains and single-strand DNA break repair, while simultaneously trapping PARP-DNA complexes on damaged DNA strands and exploiting the fundamental synthetic lethality created by PARP inhibition in tumor cells carrying germline or somatic BRCA1 or BRCA2 (BRCAm) mutations or other homologous recombination repair (HRR) gene defects supplied as film-coated tablets, 150 mg strength, 120 tablets per pot, and manufactured by Everest Pharmaceuticals Ltd. in Bangladesh.
Olaparib, the active pharmaceutical ingredient (API) of Olanib, holds the broadest FDA-approved indication portfolio of any PARP inhibitor, spanning ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer eight distinct FDA-approved indications across four tumor types, covering germline and somatic BRCA-mutated and homologous recombination-deficient (HRD) tumors in both early-stage and advanced/metastatic clinical settings. The recommended dose across all tablet-formulation indications is 300 mg (two Olanib 150 MG film-coated tablets) orally twice daily (BID) on a continuous schedule; at this dose, one 120-tablet pot of Olanib provides exactly a 30-day supply, aligning the pot size with standard monthly prescription dispensing cycles.
The pivotal Phase 3 SOLO-1 trial (NCT01844986) established first-line maintenance olaparib as the standard of care for newly diagnosed BRCAm advanced ovarian cancer, achieving a median progression-free survival (PFS) of 56.0 months versus 13.8 months with placebo at 5-year follow-up (HR 0.33; 95% CI 0.25–0.43; 67% risk reduction in disease progression or death). The Phase 3 OlympiA trial (NCT02032823) established adjuvant olaparib as the first and only PARP inhibitor to demonstrate an overall survival (OS) benefit in early breast cancer: at 6-year follow-up, OS was 87.5% versus 83.2% (HR 0.72; 95% CI 0.56–0.93) and invasive disease-free survival (IDFS) was 79.6% versus 70.3% (HR 0.72) in patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.
The Phase 3 OlympiAD trial (NCT02000622) demonstrated a 42% reduction in the risk of disease progression in gBRCAm HER2-negative metastatic breast cancer (median PFS 7.0 months versus 4.2 months; HR 0.58; p=0.0009). Important: Myelosuppression including anemia (occurring in up to 38% of patients in SOLO-1 and as Grade 3 or 4 anemia in approximately 22% of patients in clinical trials), neutropenia, and thrombocytopenia is the primary hematological toxicity of olaparib; complete blood count (CBC) with differential must be monitored at baseline, monthly for the first 12 months of treatment, and periodically thereafter, and olaparib should not be initiated until patients have recovered from hematological toxicities caused by prior chemotherapy.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib; in SOLO-1, MDS/AML occurred in 1.9% of olaparib-treated patients versus 0.8% of placebo-treated patients; permanently discontinue olaparib if MDS or AML is confirmed. Pneumonitis, including fatal cases, has occurred with olaparib; interrupt therapy for new or worsening respiratory symptoms, investigate, and permanently discontinue for confirmed pneumonitis.
Olaparib is a substrate of CYP3A; strong and moderate CYP3A inhibitors substantially increase olaparib plasma exposure and must be avoided if unavoidable, reduce the olaparib dose to 100 mg twice daily with strong inhibitors and to 150 mg twice daily with moderate inhibitors; strong and moderate CYP3A inducers substantially decrease olaparib exposure and must be avoided. Olaparib can cause embryo-fetal toxicity; females of reproductive potential must use effective contraception during treatment and for 6 months after the last dose; males with female partners of reproductive potential must use effective contraception during treatment and for 3 months after the last dose.
Venous thromboembolism (VTE), including pulmonary embolism, occurred in approximately 8% of patients receiving olaparib in prostate cancer trials. Searching for Olanib 150 MG Olaparib? Mediaid Pharmacy lists this product across its oncology medicines, breast cancer medicines, ovarian cancer medicines, prostate cancer medicines, and Everest Pharmaceuticals medicines portfolios and ships it worldwide.
Basic Product Information of Olanib 150 MG (Olaparib)
| Brand Name | Olanib 150 MG (Olaparib) |
| Product Name | Olanib |
| Generic Name | Olaparib (developmental codes AZD2281, KU0059436; a first-in-class, orally bioavailable, potent inhibitor of poly(ADP-ribose) polymerase [PARP] enzymes including PARP1, PARP2, and PARP3; a nicotinamide-based pharmacophore that exploits synthetic lethality in homologous recombination repair-deficient [HRD] tumor cells carrying germline or somatic BRCA1/2 mutations or other HRR gene alterations, trapping PARP-DNA complexes and preventing single-strand break repair; the originator brand is Lynparza, developed and commercialized jointly by AstraZeneca and Merck [MSD]; first FDA approval as the first oral PARP inhibitor ever approved: 19 December 2014, for advanced BRCA-mutated ovarian cancer following ≥3 prior lines of chemotherapy [accelerated approval]; most recent FDA approval expansions include adjuvant treatment of gBRCAm HER2-negative high-risk early breast cancer: 11 August 2022 [OlympiA]; BRCAm mCRPC in combination with abiraterone and prednisone [PROpel/MAGNITUDE]: August 2023) |
| Drug Class | PARP Inhibitor (Poly[ADP-Ribose] Polymerase Inhibitor); First-in-Class PARP1/PARP2/PARP3 Inhibitor; Synthetic Lethality Exploiter in BRCAm/HRD Tumors; PARP Trapper; DNA Damage Response (DDR) Inhibitor; Homologous Recombination Repair (HRR) Pathway Exploiter; Small-Molecule Antineoplastic Agent; Targeted Oncology Agent; Oral Cancer Medicine; Multi-Tumor-Type Targeted Therapy; BRCAm Ovarian Cancer Medicine; gBRCAm Breast Cancer Therapy; HRR Gene-Mutated Prostate Cancer Therapy; gBRCAm Pancreatic Cancer Therapy |
| Formulation | Film-Coated Tablet (oral administration; may be taken with or without food consistent administration with or without food is recommended; swallow tablets whole, do not crush, split, or chew; two 150 mg tablets are taken together per dose, administered twice daily approximately 12 hours apart; dosing is continuous no scheduled rest days within any treatment cycle; if vomiting occurs after a dose, do not take an additional dose for that dosing time resume the next scheduled dose at the next regular twice-daily interval) |
| Available Strengths | 150 mg per film-coated tablet (Olanib 150 MG; the recommended starting dose of 300 mg twice daily [BID] requires two 150 mg tablets per dose; first dose reduction for toxicity: 250 mg twice daily; second dose reduction for toxicity: 200 mg twice daily; when olaparib is used with a moderate CYP3A inhibitor that cannot be avoided, reduce the dose to 150 mg [one tablet] twice daily; when olaparib is used with a strong CYP3A inhibitor that cannot be avoided, reduce the dose to 100 mg twice daily which requires the 50 mg capsule formulation or specific dosing adjustment in consultation with the treating oncologist) |
| Available Pack Size | 120 tablets per pot (at the recommended starting dose of 300 mg twice daily [two 150 mg tablets BID = four tablets per day on a continuous schedule with no rest days], one pot of Olanib 150 MG provides exactly a 30-day supply; one pot per month aligns precisely with standard monthly prescription dispensing cycles used by oncology pharmacies, hospital formularies, and patient access programs globally; for patients on a dose-reduced schedule of 250 mg BID [one 150 mg tablet + one dose adjustment], supply planning is directed by the treating oncologist; for patients on the 150 mg BID dose-reduction level [one 150 mg tablet twice daily = two tablets/day], one pot provides a 60-day supply; for the 12-month adjuvant OlympiA-indication treatment course, the continuous 300 mg BID starting dose requires 12 pots total one pot per month for one year) |
| Dosing Schedule | Recommended Starting Dose (All Indications Tablet Formulation): Olaparib 300 mg (two Olanib 150 MG film-coated tablets) orally twice daily (BID), taken approximately 12 hours apart, with or without food, on a continuous daily schedule with no scheduled rest days. Duration by Indication: Maintenance ovarian cancer (SOLO-1/SOLO-2/PAOLA-1 indications): until disease progression or unacceptable toxicity; adjuvant breast cancer (OlympiA indication): 12 months (1 year) after completion of neoadjuvant or adjuvant chemotherapy; metastatic breast cancer (OlympiAD indication): until disease progression or unacceptable toxicity; maintenance pancreatic cancer (POLO indication): until disease progression or unacceptable toxicity; prostate cancer (PROfound/PROpel indications): until disease progression or unacceptable toxicity. Mandatory Safety Monitoring Before and During Treatment: CBC with differential at baseline, monthly for the first 12 months, then periodically thereafter; do not initiate olaparib until hematological toxicities from prior chemotherapy have resolved (ANC ≥1,500/µL; platelet count ≥100,000/µL; hemoglobin ≥9 g/dL); pregnancy test before initiating in all females of reproductive potential. Dose Reductions for Toxicity: First reduction: 250 mg BID; second reduction: 200 mg BID; withhold for Grade 3 or higher non-hematological toxicity or for hematological toxicity per prescribing information dose modification guidelines; permanently discontinue for confirmed MDS/AML or for confirmed pneumonitis. Companion Diagnostic Requirement: Confirm deleterious/suspected deleterious BRCA1/2 mutation status (germline for breast and pancreatic indications; germline or somatic for ovarian and prostate indications) or HRR gene mutation (for HRR-mutated prostate cancer indication) using an FDA-approved companion diagnostic test before initiating Olanib in the respective indication. Important Drug Interaction Guidance: Avoid concomitant strong CYP3A inhibitors (reduce dose to 100 mg BID if unavoidable); avoid concomitant moderate CYP3A inhibitors (reduce dose to 150 mg BID if unavoidable); avoid all strong and moderate CYP3A inducers; consult the treating oncologist for all dose modification decisions. |
| Primary Indications | OVARIAN CANCER: (1) First-Line Maintenance BRCAm Advanced Ovarian Cancer (SOLO-1): Olaparib 300 mg BID as maintenance therapy for adult patients with deleterious/suspected deleterious germline or somatic BRCAm advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response following first-line platinum-based chemotherapy. Based on Phase 3 SOLO-1 (NCT01844986; n=391): 5-year follow-up median PFS 56.0 months versus 13.8 months (HR 0.33; 95% CI 0.25–0.43; 67% risk reduction); 5-year PFS rate 48% versus 21%. FDA approval: December 2018. (2) First-Line Maintenance with Bevacizumab HRD-Positive Advanced Ovarian Cancer (PAOLA-1): Olaparib 300 mg BID plus bevacizumab as first-line maintenance for HRD-positive (including BRCAm) advanced ovarian, fallopian tube, or peritoneal cancer following first-line platinum-based chemotherapy with bevacizumab. Based on Phase 3 PAOLA-1: median PFS 22.1 months versus 16.6 months overall; 37.2 months versus 17.7 months in HRD-positive/BRCAm subgroup (HR 0.33). FDA approval: May 2020. (3) Maintenance of Recurrent BRCAm Ovarian Cancer (SOLO-2): Olaparib 300 mg BID as maintenance treatment of adult patients with deleterious/suspected deleterious gBRCAm recurrent epithelial ovarian cancer in complete or partial response to platinum-based chemotherapy. FDA approval: August 2017. BREAST CANCER: (5) Metastatic Breast Cancer gBRCAm HER2-Negative (OlympiAD): Olaparib 300 mg BID as monotherapy for adult patients with deleterious/suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with prior chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Based on Phase 3 OlympiAD (NCT02000622; n=302): median PFS 7.0 months versus 4.2 months versus physician’s choice chemotherapy (HR 0.58; p=0.0009; 42% risk reduction). FDA approval: January 2018. PANCREATIC CANCER: PROSTATE CANCER: (8) BRCAm mCRPC in Combination with Abiraterone (PROpel/MAGNITUDE): Olaparib 300 mg BID plus abiraterone and prednisone or prednisolone for adult patients with BRCAm mCRPC. FDA approval: August 2023. |
| Manufacturer / Brand | Everest Pharmaceuticals Ltd., Country of Origin: Bangladesh (originator molecule and brand Lynparza developed and commercialized jointly by AstraZeneca and Merck [known as MSD outside the United States and Canada]; olaparib was the first PARP inhibitor approved by the FDA for clinical use: 19 December 2014; olaparib holds the broadest indication portfolio of any PARP inhibitor across ovarian, breast, pancreatic, and prostate cancers) |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store in the original container with the lid tightly closed. Protect from moisture. Keep out of the reach of children. |
How Olanib (Olaparib) Works: PARP Trapping, Synthetic Lethality, and Homologous Recombination Repair Deficiency Exploitation in BRCA-Mutated and HRD Cancers
Olaparib (Olanib) achieves its antitumor effect through two mechanistically distinct and synergistic actions: (1) catalytic inhibition of PARP1, PARP2, and PARP3 enzymes, blocking their ability to synthesize poly(ADP-ribose) (PAR) chains and thereby preventing PARP-dependent single-strand DNA break (SSB) repair; and (2) PARP trapping the physically distinct process by which olaparib stabilizes PARP-DNA complexes on damaged DNA, preventing the natural auto-PARylation-dependent dissociation of PARP from DNA strand breaks and creating cytotoxic PARP-DNA adducts that block DNA replication fork progression.
PARP trapping is now understood to be the primary mechanism of olaparib’s anticancer potency and is the mechanistic basis for its differential activity in BRCA-mutated versus BRCA-wild-type tumors: potency as a PARP trapper, rather than simply as a catalytic inhibitor, correlates directly with cytotoxicity in cancer cells. PARP1 and PARP2 are the principal enzymes mediating SSB repair through the base excision repair (BER) pathway, in which PARP1 detects DNA SSBs, automodifies itself by synthesizing PAR chains using NAD+ as substrate, recruits SSB repair scaffold proteins (XRCC1, DNA polymerase β, DNA ligase III), and ultimately dissociates from repaired DNA after auto-PARylation.
Olaparib blocks this cycle by occupying the NAD+-binding pocket of PARP1 and PARP2 through its nicotinamide pharmacophore, competitively preventing NAD+ from binding and thereby blocking both PAR chain synthesis and PARP-dependent SSB repair. The resulting unrepaired SSBs are encountered by advancing DNA replication forks, converting single-strand lesions into double-strand DNA breaks (DSBs) the most cytotoxic form of DNA damage in replicating cells.
The therapeutic selectivity of olaparib for BRCA-mutated tumors over normal tissues is rooted in the principle of synthetic lethality the concept that simultaneous loss of two distinct DNA repair pathways is lethal to a cell, whereas loss of either pathway alone is compatible with survival. Normal cells that inherit one functional copy of BRCA1 or BRCA2 the “one-hit” heterozygous state present in all somatic cells of germline BRCA1/2 mutation carriers retain sufficient homologous recombination repair (HRR) capacity to repair olaparib-induced DSBs through the error-free HRR pathway, allowing normal-cell survival despite PARP inhibition.
In tumor cells, however, the second wild-type BRCA1 or BRCA2 allele is somatically lost (the “second hit”), producing homozygous loss of function and complete HR deficiency in the tumor cell. When PARP inhibition by olaparib prevents SSB repair in HR-deficient tumor cells, the resulting DSBs cannot be repaired by HRR and are instead processed by the error-prone non-homologous end joining (NHEJ) pathway or remain unrepaired, leading to genomic instability, chromosomal aberrations, cell cycle arrest, and ultimately tumor cell apoptosis.
This synthetic lethality framework explains why olaparib selectively kills BRCA-mutated tumor cells while sparing normal tissues a selectivity that makes olaparib mechanistically distinct from conventional chemotherapy, which causes DNA damage across all replicating cells irrespective of BRCA or HRR status. Beyond BRCA1 and BRCA2 mutations, olaparib exploits synthetic lethality in tumors with any germline or somatic mutation in the network of genes governing HRR including ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L a molecular landscape that the Phase 3 PROfound trial exploited to define its HRR-mutated mCRPC population and that provides the mechanistic rationale for olaparib’s expanding oncology indication footprint beyond BRCA-only patient selection.
The continuous twice-daily oral dosing schedule of olaparib (300 mg BID with no scheduled rest days) is designed to maintain sustained PARP inhibition throughout the treatment course, ensuring that the PARP trapping mechanism operates continuously across all replication cycles without interruption, preventing tumor cells from using inter-dose PARP activity windows to repair accumulated SSBs and resume normal replication. This continuous suppression is clinically relevant in the maintenance ovarian cancer setting where the goal of PARP inhibition is to prevent recurrence during the period of minimal residual disease (MRD) after platinum-based chemotherapy has cleared the bulk of tumor cells and in the adjuvant breast cancer setting, where the OlympiA trial demonstrated that 12 months of continuous olaparib after completion of chemotherapy capitalizes on residual HR-deficient micrometastatic tumor cells’ inability to repair PARP-induced DNA damage.
The unprecedented 5-year PFS improvement in SOLO-1 (median PFS 56.0 months versus 13.8 months; HR 0.33) is explained by olaparib’s unique ability to maintain cytostatic pressure on BRCAm ovarian cancer cells through continuous PARP trapping, preventing the micrometastatic residual tumor cells from replicating and seeding recurrence during the maintenance period an effect not replicated by chemotherapy, which is administered in cycles with treatment-free intervals that allow tumor cell recovery.
Who Should Use Olanib 150 MG (Olaparib)?
Olanib 150 MG (Olaparib) is indicated for adult patients across four distinct tumor types ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer in eight FDA-approved indications spanning first-line maintenance, adjuvant, metastatic, and combination-with-targeted-agent clinical settings. All olaparib indications require prior molecular testing by an FDA-approved companion diagnostic to confirm the relevant biomarker (germline or somatic BRCA1/2 mutation, HRD-positive status, or HRR gene mutation status) before initiating therapy. The molecular gating test for each indication determines patient eligibility and must be performed in a certified laboratory using an FDA-approved assay before the first dose of Olanib is administered.
In ovarian cancer, Olanib is indicated for three distinct patient populations. First, adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer carrying a deleterious or suspected deleterious germline or somatic BRCA1/2 mutation who are in complete or partial response following first-line platinum-based chemotherapy the SOLO-1-defined first-line maintenance indication represent the population with the most profound olaparib benefit demonstrated in clinical trials: the Phase 3 SOLO-1 trial (NCT01844986; n=391; 2:1 randomization) achieved a median PFS of 56.0 months with olaparib versus 13.8 months with placebo at 5-year follow-up (HR 0.33; 95% CI 0.25–0.43; 67% reduction in the risk of disease progression or death), establishing a clinically unprecedented difference of more than 42 months in progression-free survival that translates to approximately 3.5 years of additional disease-free time for responding patients compared to platinum chemotherapy alone.
The 5-year PFS rate was 48% with olaparib versus 21% with placebo, meaning nearly half of BRCAm ovarian cancer patients treated with olaparib maintenance remained progression-free at 5 years. Second, patients with HRD-positive advanced ovarian cancer (regardless of BRCA mutation status, as defined by the Foundation Medicine CDx assay) who completed first-line platinum-plus-bevacizumab induction therapy are candidates for olaparib plus bevacizumab maintenance per the PAOLA-1 indication, with the greatest benefit concentrated in the BRCAm/HRD-positive subgroup (median PFS 37.2 months versus 17.7 months; HR 0.33). Third, patients with deleterious/suspected deleterious gBRCAm recurrent epithelial ovarian cancer who have demonstrated a complete or partial response to platinum-based chemotherapy are candidates for maintenance olaparib per the SOLO-2-based indication.
In breast cancer, Olanib is indicated for two distinct patient populations. First, adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative, high-risk early breast cancer who have completed neoadjuvant or adjuvant chemotherapy the OlympiA-defined adjuvant indication represent the population for whom olaparib has demonstrated the most durable survival benefit: the Phase 3 OlympiA trial (NCT02032823; n=1,836; 1:1 randomization) enrolled patients with gBRCA1/2 pathogenic variant (gBRCApv) HER2-negative high-risk early breast cancer, defined as pathologically confirmed residual invasive disease after neoadjuvant chemotherapy (regardless of hormone receptor status), or stage IIA–IIIC node-positive disease after upfront surgery (for patients who went directly to surgery).
At 6-year follow-up (presented at SABCS 2024), adjuvant olaparib 300 mg BID for 12 months demonstrated: 6-year OS rate 87.5% versus 83.2% (HR 0.72; 95% CI 0.56–0.93) the first statistically significant OS benefit ever demonstrated by a PARP inhibitor in early breast cancer; 6-year IDFS rate 79.6% versus 70.3% (HR 0.72); 6-year DDFS rate 83.5% versus 75.7% (HR 0.65; 95% CI 0.53–0.81). Second, adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy are candidates for olaparib monotherapy per the OlympiAD indication (median PFS 7.0 months versus 4.2 months versus physician’s choice chemotherapy; HR 0.58; p=0.0009).
In prostate cancer, Olanib is indicated for two distinct mCRPC patient populations. First, adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC whose cancer has progressed following prior treatment with a next-generation hormonal agent (enzalutamide or abiraterone) are candidates for olaparib monotherapy per the PROfound-defined indication. The Phase 3 PROfound trial (NCT02987543) enrolled 387 men with HRR gene-mutated mCRPC and demonstrated in Cohort A (BRCA1/2 and ATM mutations): median radiographic PFS (rPFS) 7.4 months versus 3.6 months (HR 0.34; 95% CI 0.25–0.47; p<0.001) and OS HR 0.69 (95% CI 0.50–0.97; p=0.02). Second, adult patients with BRCAm mCRPC are candidates for the olaparib-plus-abiraterone combination per the PROpel/MAGNITUDE indication (FDA approval: August 2023).
Olanib is not indicated for: patients with BRCA-wild-type, HRR-intact cancers in indications requiring BRCAm or HRR mutation status (the synthetic lethality mechanism requires confirmed HR deficiency); patients who have not recovered from prior chemotherapy-induced hematological toxicities; patients with a confirmed diagnosis of MDS or AML (olaparib must be permanently discontinued); and patients who are pregnant. Ovarian cancer maintenance programs, early breast cancer adjuvant departments managing BRCA-mutated breast cancer treatment, metastatic breast cancer oncology teams, prostate cancer programs, hospital pharmacies managing oral targeted oncology medicines, and individual patients and families can contact Mediaid Pharmacy directly for Olanib 150 MG availability, pricing, and worldwide delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Olanib 150 MG (Olaparib)
Mediaid Pharmacy is a Dhaka-based supplier of specialty targeted oncology, breast cancer, ovarian cancer, prostate cancer, and rare disease medicines with worldwide shipping to patients, oncology departments, maintenance therapy programs, adjuvant treatment centers, hospital pharmacies, oncology day units, patient access programs, and international distributors across all regions. Olanib 150 MG (Olaparib), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, is supplied as 150 mg film-coated tablets in 120-tablet pots, with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The procurement significance of the 120-tablet pot format is directly tied to olaparib’s continuous twice-daily dosing architecture: at the recommended starting dose of 300 mg twice daily (two 150 mg tablets per dose, twice daily = four tablets per day, continuous with no rest days), one pot of Olanib 150 MG provides exactly a 30-day supply aligning the pot size with the standard monthly prescription dispensing cycle used by all oncology pharmacies, hospital formularies, ovarian cancer maintenance programs, and patient access programs globally. This one-pot-per-month dispensing arithmetic makes Olanib procurement planning straightforward and predictable: the 12-month OlympiA adjuvant course for high-risk early breast cancer patients requires 12 pots (one per month for 12 consecutive months); maintenance ovarian cancer programs dispensing on a monthly cycle also receive one pot per dispensing visit.
For patients receiving olaparib as part of a combination regimen (with bevacizumab in ovarian cancer or with abiraterone in prostate cancer), Olanib supply aligns naturally with the monthly dispensing cycles of the partner agents. Ovarian cancer maintenance programs; adjuvant breast cancer therapy centers sourcing olaparib for gBRCAm early breast cancer patients; prostate cancer oncology departments managing PROfound-indication olaparib programs; hospital formulary procurement departments co-sourcing Olanib with other oral targeted oncology medicines; and individual patients and families accessing olaparib for BRCA-mutated ovarian cancer treatment can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for Olanib 150 MG stock availability, current pricing, and international delivery timelines.
Why Choose Olanib 150 MG (Olaparib) from Mediaid Pharmacy?
Olanib (Olaparib) from Everest Pharmaceuticals Ltd. delivers the validated synthetic lethality mechanism of the first-in-class PARP inhibitor olaparib a molecule with the broadest indication portfolio of any PARP inhibitor, spanning eight FDA-approved indications across ovarian, breast, pancreatic, and prostate cancers, including the landmark first-line maintenance SOLO-1 ovarian indication, the survival-benefit-demonstrating OlympiA adjuvant breast cancer indication, the groundbreaking OlympiAD metastatic breast cancer indication, the POLO pancreatic maintenance indication, and the PROfound/PROpel prostate cancer indications as a precisely formulated 150 mg oral film-coated tablet in a 120-tablet pot providing exactly a 30-day supply at the recommended 300 mg BID starting dose. Olaparib is pharmacologically and clinically distinguished across the targeted oncology landscape by four evidence-based attributes.
First, olaparib is the first and only PARP inhibitor to demonstrate an overall survival benefit in early breast cancer the OlympiA trial (n=1,836; 6-year OS 87.5% versus 83.2%; HR 0.72; 95% CI 0.56–0.93) establishing that one year of adjuvant olaparib after (neo)adjuvant chemotherapy translates the PARP inhibitor synthetic lethality mechanism into a durable, statistically significant reduction in the risk of death in gBRCAm HER2-negative high-risk early breast cancer patients. The 6-year invasive disease-free survival improvement (79.6% versus 70.3%) and the 6-year distant disease-free survival benefit (83.5% versus 75.7%; HR 0.65; 95% CI 0.53–0.81) achieved across the full follow-up of the OlympiA trial confirm that the survival advantage of adjuvant olaparib is durable and not diminished by longer follow-up. This OS benefit has made olaparib the first systemic oncology agent other than chemotherapy or endocrine therapy to demonstrate an overall survival advantage in early breast cancer in the BRCA-mutated subpopulation.
Second, olaparib achieves the most substantial progression-free survival improvement ever demonstrated by any maintenance therapy in first-line ovarian cancer in the BRCAm population the SOLO-1 trial’s 5-year result of a median PFS of 56.0 months versus 13.8 months (HR 0.33; 67% risk reduction) translates to approximately 3.5 additional progression-free years for a population (newly diagnosed advanced ovarian cancer) in which the historical standard of care (platinum-based chemotherapy alone) achieved a median PFS of approximately 14 months before disease recurrence and the initiation of further therapy. This magnitude of PFS benefit a more than 4-fold improvement in median PFS is unprecedented in phase 3 ovarian cancer maintenance trials and has fundamentally redefined the treatment paradigm for newly diagnosed BRCAm advanced ovarian cancer, with SOLO-1 establishing olaparib as the standard first-line maintenance backbone.
Third, olaparib is the PARP inhibitor with the broadest tumor-type indication coverage four tumor types (ovarian, breast, pancreatic, prostate) with eight distinct FDA-approved indications providing clinicians and healthcare institutions managing multi-tumor-type cancer care programs the ability to source a single PARP inhibitor formulation that covers the entire spectrum of BRCA-mutated and HRD cancers across the institution, simplifying formulary management, pharmacist familiarity, and procurement planning. No other PARP inhibitor carries FDA-approved indications spanning all four of these tumor types simultaneously.
Fourth, olaparib is an orally self-administered, twice-daily tablet taken on a simple continuous schedule with no rest days or cycle breaks two tablets (300 mg) in the morning and two tablets (300 mg) in the evening, every day, with or without food enabling complete outpatient management with straightforward adherence, predictable one-pot-per-month procurement, and no requirement for infusion clinic visits for drug administration. Olanib 150 MG is manufactured by Everest Pharmaceuticals Ltd. and is available through Mediaid Pharmacy in 120-tablet pots.
To source the complete range of PARP inhibitor therapies, breast cancer medicines, ovarian cancer medicines, prostate cancer medicines, and oncology medicines, visit the Mediaid Pharmacy breast cancer medicines portfolio, ovarian cancer medicines portfolio, prostate cancer medicines portfolio, the oncology medicines collection, and the Everest Pharmaceuticals medicines range, and contact the team for a personalized quotation.
Frequently Asked Questions About Olanib 150 MG (Olaparib)
What is Olanib 150 MG (Olaparib) used for?
Olanib 150 MG (Olaparib) is an oral first-in-class PARP (poly[ADP-ribose] polymerase) inhibitor with eight FDA-approved indications across four tumor types. In ovarian cancer: (1) first-line maintenance of BRCAm advanced ovarian cancer after platinum-based chemotherapy (SOLO-1; median PFS 56.0 months vs 13.8 months; HR 0.33; 67% risk reduction); (2) first-line maintenance with bevacizumab for HRD-positive advanced ovarian cancer (PAOLA-1); (3) maintenance of recurrent gBRCAm ovarian cancer after platinum chemotherapy (SOLO-2). In breast cancer: (4) adjuvant treatment for 12 months in gBRCAm HER2-negative high-risk early breast cancer (OlympiA; 6-year OS 87.5% vs 83.2%; HR 0.72; first and only PARP inhibitor to show OS benefit in early breast cancer; FDA approval: August 2022); (5) gBRCAm HER2-negative metastatic breast cancer after prior chemotherapy (OlympiAD; median PFS 7.0 months vs 4.2 months; HR 0.58; FDA approval: January 2018). In pancreatic cancer: (6) first-line maintenance of gBRCAm metastatic pancreatic adenocarcinoma after platinum-based chemotherapy (POLO). In prostate cancer: (7) HRR gene-mutated mCRPC after progression on enzalutamide or abiraterone (PROfound; Cohort A rPFS HR 0.34; p<0.001; OS HR 0.69; p=0.02); (8) BRCAm mCRPC in combination with abiraterone (PROpel/MAGNITUDE). The recommended dose is 300 mg (two Olanib 150 MG tablets) twice daily on a continuous schedule. Olanib 150 MG, 120 tablets per pot, is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and is available through Mediaid Pharmacy with worldwide shipping.
What is the generic name of Olanib?
The generic name of Olanib is olaparib (developmental codes AZD2281 and KU0059436). Olaparib is an orally bioavailable, potent, first-in-class inhibitor of poly(ADP-ribose) polymerase 1 and 2 (PARP1/2), belonging to the class of PARP inhibitors that exploit synthetic lethality in cancer cells carrying BRCA1/2 mutations or other homologous recombination repair (HRR) gene defects. Olaparib’s mechanism of action encompasses two synergistic components: catalytic PARP inhibition, which prevents PARP-mediated single-strand DNA break repair, and PARP trapping, in which olaparib stabilizes toxic PARP-DNA complexes on damaged DNA strands that cannot be resolved in HR-deficient tumor cells. Olaparib was the first oral PARP inhibitor ever approved by the FDA (19 December 2014) and remains the PARP inhibitor with the broadest FDA-approved indication portfolio, covering eight indications across ovarian, breast, pancreatic, and prostate cancers. The originator brand of olaparib is Lynparza, developed and commercialized jointly by AstraZeneca and Merck. Olanib is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and is available as 150 mg film-coated tablets in 120-tablet pots. Mediaid Pharmacy distributes Olanib (Olaparib) globally with worldwide shipping to patients, oncology departments, hospital pharmacies, and BRCA-mutated cancer treatment programs worldwide.
What is the difference between olaparib, niraparib, and rucaparib as PARP inhibitors for ovarian cancer?
Olaparib (Olanib/Lynparza), niraparib (Zejula), and rucaparib (Rubraca) are all oral PARP inhibitors approved for ovarian cancer maintenance but differ in PARP selectivity profile, indication breadth, patient selection requirements, dosing schedule, and clinical evidence across other tumor types. Olaparib (PARP1/2/3 inhibitor) has the broadest indication portfolio eight FDA-approved indications across four tumor types (ovarian, breast, pancreatic, prostate) including the only PARP inhibitor approval for adjuvant treatment of early breast cancer (OlympiA) and for HRR gene-mutated mCRPC (PROfound), and is the first and only PARP inhibitor to demonstrate an OS benefit in early breast cancer; it requires companion diagnostic confirmation (BRCAm or HRD-positive) for all ovarian maintenance indications. Niraparib is dosed once daily (continuous) and was approved for ovarian cancer maintenance irrespective of BRCA mutation status in certain settings, without mandatory biomarker gating for all populations; however, niraparib does not carry breast, pancreatic, or prostate cancer indications equivalent to olaparib’s scope. Rucaparib (PARP1/2/3 inhibitor, twice-daily continuous dosing) was approved for BRCAm recurrent ovarian cancer treatment and maintenance in the platinum-sensitive setting; its marketed indications were narrower than olaparib’s and rucaparib was withdrawn from the US market by Clovis Oncology in 2022. The PARP trapping potency order among approved inhibitors (talazoparib > niraparib > rucaparib > olaparib in preclinical assays) does not directly translate to clinical efficacy ranking, as olaparib’s combination of potent PARP trapping, sustained clinical development across four tumor types, and the most comprehensive phase 3 evidence base of any PARP inhibitor has established it as the class-defining clinical agent. Visit the Mediaid Pharmacy ovarian cancer medicines collection for the complete PARP inhibitor and gynecologic oncology portfolio.
What are the side effects of Olanib (Olaparib)?
The most clinically significant adverse effects of olaparib are myelosuppression (anemia, neutropenia, thrombocytopenia), nausea, fatigue, MDS/AML, and pneumonitis. Nausea (77%) and fatigue (67%) are the most common adverse reactions and are typically manageable with antiemetics, dietary modifications, and dose scheduling optimization. Anemia occurred in 38% of patients in SOLO-1 (Grade 3 or 4 anemia approximately 22% across clinical trials) and is the most clinically significant hematological toxicity; CBC monitoring at baseline, monthly for the first 12 months, and periodically thereafter is mandatory; transfusions are used as clinically indicated for symptomatic anemia. Neutropenia and thrombocytopenia also occur and require the same CBC monitoring schedule. Abdominal pain (45%), vomiting (40%), diarrhea (37%), and constipation are common gastrointestinal effects that are typically low grade and manageable. Myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML): reported in 1.9% of patients in SOLO-1 and in <1–2% of patients across clinical trials; fatal cases have occurred; permanently discontinue olaparib and treat accordingly if MDS or AML is confirmed. Pneumonitis: rare but potentially fatal; interrupt therapy for new or worsening respiratory symptoms, investigate promptly, and permanently discontinue for confirmed pneumonitis. Venous thromboembolism (VTE): occurred in approximately 8% of patients in prostate cancer trials; monitor for signs and symptoms of DVT and pulmonary embolism. Always establish baseline CBC, liver function tests, creatinine, and pregnancy status before initiating Olanib under the supervision of an experienced oncologist.
How effective is olaparib for BRCA-mutated ovarian cancer?
Olaparib demonstrated clinically unprecedented and statistically significant progression-free survival benefit in BRCAm advanced ovarian cancer in the Phase 3 SOLO-1 trial (NCT01844986) the defining Phase 3 study establishing first-line olaparib maintenance as the standard of care following platinum-based chemotherapy in this population. SOLO-1 enrolled 391 patients with newly diagnosed, advanced (FIGO Stage III/IV) BRCA1/2-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy and randomized them 2:1 to olaparib 300 mg BID versus placebo. The primary endpoint at the initial 2018 analysis was met with HR 0.30 (95% CI 0.23–0.41; p<0.001). At the 5-year follow-up data cut, the median PFS was 56.0 months with olaparib versus 13.8 months with placebo (HR 0.33; 95% CI 0.25–0.43; 67% risk reduction); the 5-year PFS rate was 48% with olaparib versus 21% with placebo, meaning nearly half of BRCAm ovarian cancer patients receiving olaparib maintenance were still progression-free at 5 years an outcome that had been historically impossible with standard-of-care platinum chemotherapy alone in this disease. SOLO-1 established the longest duration of follow-up for any PARP inhibitor in the newly diagnosed advanced ovarian cancer setting and demonstrated that the PFS benefit of first-line olaparib maintenance does not wane over time, with the 5-year PFS curves remaining separated. Olanib 150 MG (Olaparib) is available through Mediaid Pharmacy with worldwide shipping; visit the ovarian cancer medicines collection for the complete BRCA-mutated cancer therapy portfolio.
Is Olanib (Olaparib) safe during pregnancy or while breastfeeding?
Olanib (Olaparib) can cause fetal harm based on its mechanism of action and animal reproductive toxicology findings. Inhibition of PARP-mediated DNA repair by olaparib disrupts the rapid DNA replication required for normal embryonic organogenesis, placental development, and fetal tissue formation throughout all trimesters of gestation; animal reproductive toxicology studies demonstrated embryo-fetal lethality, fetal malformations, and growth retardation at exposures below the recommended human dose, consistent with the essential roles of PARP-dependent DNA repair in normal embryonic development. Females of reproductive potential must use effective contraception during olaparib treatment and for 6 months after the last dose. Males with female partners of reproductive potential must use effective contraception during olaparib treatment and for 3 months after the last dose. Olaparib may impair male fertility based on findings from animal reproductive toxicology studies demonstrating testicular toxicity; male patients should be advised of this potential risk and offered discussion of fertility preservation options (sperm banking) with the treating oncologist before initiating Olanib therapy, particularly for the 12-month adjuvant OlympiA indication where prolonged treatment is involved. There are no data on the presence of olaparib or its metabolites in human breast milk; because of the potential for serious adverse reactions including DNA damage and cell death in a breastfed infant, breastfeeding is not recommended during olaparib treatment and for 1 month after the last dose. Verify pregnancy status with a serum or urine pregnancy test before initiating Olanib in all females of reproductive potential. Discuss all aspects of reproductive planning, contraceptive requirements, and fertility counseling with the treating oncologist before starting olaparib therapy.
Do I need a BRCA test before taking Olanib (Olaparib)?
Yes. Companion diagnostic testing for BRCA1/2 mutation status (germline, somatic, or both depending on the indication) or HRR gene mutation status is required before initiating Olanib (Olaparib) for each of its FDA-approved indications. For the breast cancer indications (OlympiA adjuvant and OlympiAD metastatic), FDA-approved germline BRCA testing (such as the BRACAnalysis CDx assay by Myriad Genetics or the FoundationOne CDx assay) must confirm a deleterious or suspected deleterious germline BRCA1 or BRCA2 pathogenic variant before olaparib is initiated. For the ovarian cancer first-line maintenance indication (SOLO-1), FDA-approved germline or somatic BRCA testing is required to confirm BRCAm status; for the PAOLA-1 HRD-positive ovarian cancer indication, the Foundation Medicine CDx assay is the FDA-approved companion diagnostic used to confirm HRD-positive status. For the PROfound prostate cancer indication, an FDA-approved companion diagnostic for HRR gene mutation testing (somatic or germline) must confirm a deleterious or suspected deleterious alteration in BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L before initiating olaparib monotherapy in mCRPC. Companion diagnostic testing is not optional it is a regulatory and clinical requirement for each indication, and Olanib should not be prescribed without confirmed biomarker-positive status by an FDA-approved test. Patients who test negative for the required biomarker are not candidates for the respective olaparib indication. Contact Mediaid Pharmacy for Olanib 150 MG availability; your treating oncologist will determine the appropriate companion diagnostic test, interpret results, and confirm eligibility before initiating olaparib for BRCA-mutated breast cancer or other BRCA-mutated cancer indications.
Can I order Olanib 150 MG (Olaparib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Olanib 150 MG (Olaparib), film-coated tablets, 120 tablets per pot, manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, to patients, ovarian cancer oncology departments, adjuvant breast cancer treatment programs, metastatic breast cancer treatment units, prostate cancer oncology departments, pancreatic cancer programs, hospital pharmacies, oncology day units, patient access programs, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, shipping options, and international delivery details for your country.
Order Olanib 150 MG (Olaparib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.